Probenecid And Colchicine

Quick links

Choose a section

Quick links to important sections

Advertisements

Probenecid And Colchicine

Selected form

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Probenecid And Colchicine

Property Description
Active ingredient Probenecid and Colchicine
Form Fixed-dose combination oral tablet
Pharmacological class Uricosuric combination, Anti-gout agent
General purpose Management of hyperuricemia and chronic gout
Origin Synthetic (Probenecid) and Natural Alkaloid (Colchicine)

Probenecid And Colchicine is a prescription-only medication formulated as a fixed-dose combination oral tablet utilized for the long-term management of high blood uric acid levels, known as hyperuricemia, a condition central to gout. This medicine is recognized as a uricosuric combination, a type of anti-gout agent that provides a synergistic, two-pronged approach to the chronic condition.


Composition and Origin of the Dual-Action Tablet

The oral tablet contains two primary active ingredients, Probenecid and Colchicine, which function together to achieve a beneficial pharmacological synergy. Probenecid is a compound classified as synthetic that primarily aids in the removal of uric acid, while Colchicine is an alkaloid derived from a natural source that exhibits an anti-inflammatory agent effect. The fixed ratio of the two agents in this combination therapy is a key feature, intended to ensure the patient receives continuous, multi-targeted support for both metabolic correction and inflammatory management.

Probenecid's main role is enhancing the uric acid excretion in the kidneys, which ultimately lowers the concentration of urate in the blood.


General Purpose: Why Use a Uricosuric Combination?

The general purpose of this medication is to achieve and sustain reduced serum urate levels and contribute to the long-term stability necessary for patients managing chronic gouty arthritis. By combining an agent that promotes uric acid excretion with one that disrupts the activity of inflammatory cells, the medicine helps decrease the overall body burden of uric acid. This dual approach is regarded as an effective strategy for preventing the recurrence of painful gout episodes, addressing both the cause and effect of the condition.

Regulatory References

  1. Probenecid and Colchicine Drug Information
Advertisements

What side effects are possible with Probenecid And Colchicine?

Possible Side Effects and Safety Information

The safety profile for the Probenecid and Colchicine combination is based on adverse reactions officially categorized by system-organ class. The most frequently reported adverse events primarily involve the Gastrointestinal Disorders, including common effects like mild diarrhea, nausea, vomiting, and abdominal pain. Other documented reactions span the Dermatological system (e.g., dermatitis, urticaria, alopecia) and the Nervous System (headache, dizziness).

Serious Adverse Reactions

Official regulatory documents note the potential for rare but serious adverse reactions. These include life-threatening Blood and Lymphatic System Disorders such as aplastic anemia, leukopenia, and agranulocytosis. Severe damage to the Hepatobiliary Disorders, specifically hepatic necrosis, has also been documented. Additionally, severe systemic reactions like anaphylaxis and Stevens-Johnson Syndrome (SJS) are listed in the safety information.

Time-Related Safety Patterns

The prescribing information notes that the risk of certain events is tied to the phase of treatment. The precipitation or exacerbation of acute gouty arthritis may occur during the initial phase of therapy, even as serum uric acid levels begin to fall. Conversely, neuromuscular toxicity and rhabdomyolysis have been reported with chronic, long-term exposure to the colchicine component.

Population and Constraint Considerations

The drug is subject to specific safety constraints. It is contraindicated in individuals with a known history of blood dyscrasias or uric acid kidney stones. For patients with renal or hepatic impairment, use is prohibited when they are also taking P-gp or strong CYP3A4 inhibitors due to a high risk of fatal toxicity. Safety considerations are also defined for older adults, whose dosage may be adjusted based on renal function, and for children under the age of two, for whom the medication is contraindicated.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Probenecid And Colchicine

Property Official Regulatory Statement (Strictly Label-Derived)
Documented Overdose Presentations Initial (Gastrointestinal): Severe Nausea, Vomiting (may be continuous), Abdominal Pain, and Severe Diarrhea (may be bloody). Systemic: Confusion, Hypotension, Volume Depletion, and Electrolyte Abnormalities.
Physiological Systems Affected Gastrointestinal Tract, Cardiovascular System, Hematological System, Renal System, Hepatic System, Neurological System.
Population-specific Overdose Notes Increased risk of toxicity is documented for patients with existing Renal Impairment or Hepatic Impairment, Cardiac Disease, and those at the extremes of age.
Emergency-response Statements Immediate medical attention must be sought. Stop taking this medicine immediately if severe gastrointestinal symptoms occur. Specialist medical advice should be promptly obtained.

Official Overdose Statements:

  • The regulatory profile confirms that fatal overdoses have been reported with this combination.
  • Initial gastrointestinal symptoms may rapidly progress to delayed systemic toxicity, including Multiple Organ Failure, Cardiovascular Collapse, and severe Bone Marrow Suppression (Myelosuppression).
  • No specific antidote is known to counter the toxic effects of the Colchicine component.
  • Management is limited to general symptomatic and supportive measures, requiring mandatory monitoring of vital signs, ECG, and blood indices for at least 6 to 12 hours after ingestion.

Connection to the overall overdose profile: Regulatory documents define the overdose profile based on the life-threatening toxicity of the Colchicine component, which necessitates that all suspected ingestions require immediate medical attention. This guidance emphasizes the documented severity, the risk of delayed progression, and the official finding that effective elimination procedures or a specific antidote are unavailable.

Advertisements

Therapeutic Uses of Probenecid And Colchicine

This combination medicine plays a role in managing conditions characterized by chronic gouty arthritis through a dual-action approach. The primary indication is for the management of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout. The medication is commonly used to help with hyperuricemia, conditions associated with systemic imbalance, such as sustained, elevated uric acid in the blood, and is applied in clinical settings that involve episodic or fluctuating manifestations of gout.

This therapy supports the patient in achieving and maintaining stable serum urate concentrations, which is a relevant goal for long-term stability. It is generally used to help ease the symptom burden of acute episodes by providing supportive relief during flare-ups. This metabolic correction may assist with maintaining a sense of long-term stability and supports the maintenance of functional stability against structural changes, such as the formation of tophi. The support against recurrent gout episodes is a key aspect of the patient-oriented benefit, which helps patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.


Quick Fact: Relief for Recurrent Gout Flare-Ups

The medicine is applied in addressing conditions marked by periods of heightened symptoms, offering symptomatic relief that helps patients cope more steadily with difficult episodes.

Regulatory References

  1. DailyMed listing via the NIH
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Probenecid And Colchicine?

This section outlines the population eligibility and restrictions for Probenecid And Colchicine, strictly based on official regulatory documentation.

Absolute Contraindications

The medicine is absolutely contraindicated and must not be used in several patient groups:

  • Patients with known hypersensitivity to probenecid, colchicine, or aspirin.
  • Individuals diagnosed with blood dyscrasias or uric acid kidney stones.
  • Pregnant patients and children under 2 years of age.

Condition and Age Restrictions

Use is highly restricted or subject to limitations based on physical condition and age:

  • Renal Function: The medicine may not be effective in patients with severe chronic renal insufficiency (GFR le 30 mL/min).
  • Hepatic Function: Caution is required for patients with hepatic dysfunction due to the potential for increased colchicine toxicity.
  • Timing: Therapy must not be started during an acute gouty attack.
  • Pediatric Use: Use for gout is not established in children; studies have been performed only in adults.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Probenecid and Colchicine based on two main mechanisms: the inhibition of renal transporters by Probenecid and the metabolic clearance of Colchicine.

Co-administration with Salicylates (Aspirin) is formally contraindicated because they antagonize the uricosuric action of the Probenecid component. Furthermore, the combination is contraindicated in patients with renal or hepatic impairment when co-administered with Dual P-glycoprotein (P-gp) and strong CYP3A4 inhibitors, due to the risk of life-threatening colchicine exposure.

Probenecid significantly increases the plasma levels of co-administered medicines that are normally cleared by the kidneys, such as Penicillins, Cephalosporins, and Methotrexate. This is a pharmacokinetic interaction resulting from the inhibition of renal tubular secretion. Conversely, strong inhibitors of CYP3A4 (e.g., Clarithromycin) and P-gp (e.g., Cyclosporine) significantly increase systemic colchicine concentration.

The regulatory profile also documents pharmacodynamic interactions, including an increased risk of myopathy when co-administered with drugs known to cause myotoxicity, such as Statins. Consumption of Grapefruit/Grapefruit Juice must be avoided as it inhibits both CYP3A4 and P-gp pathways.

Advertisements

Mechanism of Action

The mechanism of action is defined by two complementary domains. Probenecid acts as a competitive inhibitor of the URAT1 transporter in the kidney's proximal tubules. By blocking this transporter, filtered uric acid is prevented from being reclaimed, leading to enhanced renal clearance and a sustained reduction in circulating serum urate levels. This process leads to a lower steady-state concentration of serum urate.

The second domain is governed by Colchicine, which binds directly to the protein tubulin, thereby inhibiting the formation of microtubules within immune cells. This structural disruption impairs cellular processes like chemotaxis and indirectly blocks the activation of the NLRP3 Inflammasome complex. The resulting cascade suppresses the release of pro-inflammatory mediators (IL-1beta), which limits the inflammatory cellular response in affected tissue.

The combination alters the systemic metabolic pathway via urate reduction and provides a targeted modulation of the cellular inflammatory response, resulting in a complementary effect on both urate transport and local cell activity.

Advertisements

Dosage and Administration Information

This medication is administered via the oral route as a fixed-dose combination tablet. Its use is guided by a phased schedule and specific administration instructions.

Dosing Schedule and Administration

The initiation of therapy should not begin until any acute gouty attack has fully subsided. The adult dosage regimen starts with one tablet daily (containing 500 mg Probenecid and 0.5 mg Colchicine) for the first seven days. The dose is then increased to the standard maintenance dose of one tablet twice daily.

For chronic control, the daily dosage may be adjusted upward by one tablet every four weeks, as tolerated, if symptoms are uncontrolled, generally not exceeding four tablets per day. Conversely, the long-term maintenance dose may be gradually reduced by one tablet every six months once acute attacks have been absent for six months or more and serum urate levels are stable.

Procedural Conditions for Use

To help prevent uric acid crystallization in the urine, a liberal fluid intake (e.g., 2 L/day) is recommended. Instructions also advise using urine alkalizing agents, such as sodium bicarbonate (3 to 7.5 g/day) or potassium citrate (7.5 g/day), especially during periods of high uric acid excretion. The tablet may be taken with food if needed to manage gastric tolerance. If an acute attack occurs during maintenance therapy, the current dosage is continued without change, and additional colchicine is administered to control the flare. Safety and efficacy for patients under 18 years of age have not been established.

Advertisements

Recent Clinical Evidence

Research Evidence Supporting the Use in Chronic Gout

This section summarizes the official research record that relates to the medicine's official status. The evidence for this fixed-dose combination was studied for its role in the long-term management of chronic gouty arthritis, especially in conditions characterized by recurrent, acute attacks of gout. The primary evidence for this combination therapy refers to research concerning the individual agents, Probenecid and Colchicine.

Research explored how the combination was evaluated in patient groups experiencing cycles of stability and flare-ups. These studies monitored changes related to systemic or functional imbalance, specifically focusing on physiological changes that were measured. Findings describe patterns observed in these studies.

Primary Outcomes Measured in Gout Studies

The research examined several core outcomes to understand the medicine’s profile. Studies explored changes in serum urate (sUA) levels, which are outcomes related to systemic imbalance. The research also monitored clinical event frequency, specifically tracking the occurrence of acute gout flares in observed populations.

Research also included studies conducted during periods of increased symptom activity, where research examined temporary physiological imbalance by tracking symptom intensity or variability, which relates to physical discomfort, over defined time intervals. Findings help contextualize how patients reported their experience during short-term or episodic symptom patterns.

Long-Term Studies and Follow-Up

Research examined the medicine's role in the context of long-term management for conditions characterized by fluctuating manifestations. However, the follow-up durations for some of the original, key clinical investigations were limited and focused on short-term or intermediate outcomes. Long-term effects are not fully established in modern, large-scale studies specifically on the fixed-dose combination product.

Evidence Profile in Specific Patient Groups

The research record for this combination product has focused primarily on adult patients with chronic gout. Data for certain patient groups remain insufficient. Specifically, information for the use of this medicine in pediatric populations remains limited, and research exploring its effects in children has not been a focus of the evidence base cited in regulatory summaries.

What Remains Uncertain About the Research for This Combination

The evidence landscape presents several limitations. The evidence level varies across studies and is generally considered Moderate-Low, as the research refers to the established data for the two individual components rather than recent, large-scale Randomized Controlled Trials (RCTs) for the combined dosage. Consequently, sample sizes were modest in some instances, and follow-up durations were limited. The research provides context but not individual predictions.

Key Studies & References

  1. Probenecid and Colchicine Tablet, official prescribing information (DailyMed)
  2. Colchicine Tablet, official prescribing information (DailyMed)
  3. 2020 American College of Rheumatology Guideline for the Management of Gout
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Probenecid And Colchicine (FAQ)


Q: Can Probenecid And Colchicine be used during an acute gout flare-up?

Official regulatory documents state that therapy with this combination medicine should not be started while a patient is experiencing an acute gouty attack. However, if a gout flare occurs while a person is already on maintenance therapy, the current dosage is continued without change, and a healthcare provider will likely administer additional colchicine separately to manage the acute symptoms, while the combination drug is continued.


Q: Is hair loss a possible side effect of Probenecid And Colchicine?

Yes, hair loss, medically known as alopecia, is listed as one of the reported adverse reactions in the official product information for this medicine. If hair changes are observed, regulatory guidance suggests consulting with a healthcare provider.


Q: What should I do if I notice a rash after starting Probenecid And Colchicine?

Official regulatory information notes that skin reactions, such as dermatitis or a rash, are possible side effects. While mild reactions may occur, patients are generally advised to notify a healthcare provider of any skin change. Severe rash is listed as a symptom that requires immediate medical attention, as it could indicate a serious systemic reaction.


Q: How long do people usually stay on Probenecid And Colchicine therapy?

The duration of therapy is based on individual patient needs and is determined by a healthcare provider. Official regulatory labeling indicates that once acute gout attacks have been absent for six months or more and serum uric acid levels are stable, the long-term maintenance dose may be gradually reduced over time. The overall aim of the treatment is sustained control of the condition.


Q: Is Probenecid And Colchicine a cure for gout?

No. Official regulatory documents indicate this drug is used for the management of chronic gouty arthritis. Its purpose is to help reduce the incidence of acute gout attacks and lower the body’s burden of uric acid. It is not considered a cure for the underlying chronic condition.


Q: Will Probenecid And Colchicine help with all types of arthritis?

No. According to official product labeling, this medicine is indicated specifically for the treatment of chronic gouty arthritis that is complicated by frequent, recurrent, acute attacks of gout. It is not generally indicated for other types of arthritis.


Q: Does Probenecid And Colchicine interact with any common blood pressure medications?

The Probenecid component can affect how the body handles other medicines. Regulatory information indicates it significantly increases the plasma levels of many co-administered medicines that are normally cleared by the kidneys. If a patient is taking blood pressure medication, consultation with a healthcare provider is necessary, as drug levels may require monitoring.


Q: Are there special monitoring requirements (like blood tests) when on this drug?

Yes, monitoring is generally required. The dosage is often adjusted to maintain specific serum uric acid levels, which necessitates blood tests. Additionally, because the drug can potentially cause serious blood disorders (blood dyscrasias), a healthcare provider may order specific tests to monitor blood cell counts.


Q: Does taking Probenecid And Colchicine mean I will never get another gout attack?

The medicine is used to reduce the frequency and incidence of recurrent acute gout attacks. However, official warnings state that a new gout flare or an exacerbation can still occur while taking the medicine, especially during the initial phase of therapy.

Advertisements

How should Probenecid And Colchicine be stored and disposed of?

Storage and Disposal Requirements

The following rules for storing and disposing of Probenecid and Colchicine tablets are based strictly on official governmental regulatory documents.

Storage Condition Requirement
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Protection Protect from light and moisture; store in a cool, dry place.
Child Safety Keep out of the reach of children due to the high toxicity risk of the colchicine component.

For disposal, unused or expired Probenecid and Colchicine should be safely discarded using a drug take-back program or mail-back service. If these options are unavailable, the FDA advises mixing the tablets with an undesirable substance, such as used coffee grounds or dirt, sealing the mixture in a container, and placing it in the household trash. The tablets must not be flushed down a sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Probenecid And Colchicine found in:

A-Z Index: